2nd annual cell based assays (2011) pp
DESCRIPTION
Email [email protected] for early bird discountTRANSCRIPT
11th – 13th October 2011, Visiongain Conference Centre, London, UK
Organised By
Optimising methods and integrating new platforms for drug discovery, development and toxicity testing
To Book Call: +44 (0) 20 7336 6100 | www.visiongain.com/cell-based-assays
Julie Holder, Preclinical Director, Stem Cell DPU, GlaxoSmithKline
Stefan Otto Mueller, Director, Early, Genetic and Molecular Toxicology, Merck Serono
Rachel Russell, Director, Primary Pharmacology Group, Pfizer
Darren Cawkill, Associate Director, Primary Pharmacology Group, Pfizer
Miroslav Cik, Research Fellow, Janssen Pharmaceutica (Johnson & Johnson)
Joanne Bowes, Principal Scientist, AstraZeneca
Magalie Rocheville, Investigator, GlaxoSmithKline
Stephen Minger, Global Head of R&D, Cellular Technologies, GE Healthcare
Frank W. Bonner, Chief Executive, Stem Cells for Safer Medicines
Mark Slack, Group Leader, Cellular Assays, Evotec
Jasmin Fisher, Researcher, Executable Biology, Microsoft Research Cambridge
Molly Stevens, Professor of Biomedical Materials and Regenerative Medicine, Imperial College London
David C. Hay, Principal Investigator, MRC Centre for Regenerative Medicine, University of Edinburgh
Stefan Przyborski, Founder and Chief Scientific Officer, Reinnervate
Key Speakers
BOOK NOW!
2nd Annual Cell-Based Assays
Driving the Industry Forward | www.futurepharmaus.com
Media Partners
Pre-conference Workshop, Tuesday 11th October, 2011
Industrial application of pluripotent stem cells and their derivatives- High-content screening as a valuable tool for drug discovery and toxicity testing
Led by: Mikael Englund, Senior Scientist, Site Manager, Cellartis, Daniella Steel, Senior Scientist, Project Leader, Cellartis, Paul Andrews, Senior Scientist, Drug Discovery Unit, University of Dundee
Panellists: Petter Björquist, Senior Principal Scientist, Project Manager, Cellartis, Anders Aspegren, Senior Scientist, Production Manager, Cellartis
Associate SponsorP H O T O N I S O U R B U S I N E S S
Conference Introduction2nd Annual Cell-Based Assays
11th - 13th October 2011, London, UK
Dear Colleague, Ittakeswellover£500millionandbetween10and12yearstodevelopanewdrug.
For every million compounds screened, approximately 250 make it to pre-clinicaltesting,10advancetoclinicaltrialsandjustoneisapprovedforpatientuse.Industrycanill-affordtocontinuesuchawastefulprocess.
Cancerousandanimalcells,manyhavingbeen incontinuousculture fordecades,poorly reflectpatientphysiology.These,finally,areyieldingtomorerepresentativemodels that better reflect the intended recipients of new molecular entities.Advances in label-free technologies, human primary, 3D and embryonic-stem cellderived lines are heralding a paradigm shift in drug discovery, development andtoxicitytesting.
Focussing on these, the future tools that better reflect PK/PD, genomic andphenotypic differences within and between human populations,Visiongain bringsyouitssecondCell-BasedAssaysconference.
Attending this event will empower you to: •Utilisenewtechniquesinhighthroughputscreening. •Identify intracellular transduction cascades for G-protein coupled receptors and
kinases. •Acceleratehigh-contentscreeningusingprimarycells. •Incorporate computationalmodels to study the effects of drugs on intracellular
networks. •Use3D cell assays formore relevant testingof the effects of drugsonorgans,
includingtheliver,heartandbraincells. •Harness human embryonic, adult and induced pluripotent stem cells for drug
discovery,developmentandtoxicitytesting. Ilookforwardtomeetingyouattheconference Bestregards
Nicholas Stone Head of Conferences
Who should attend?Presidents, Chief Executive Officers, VPs, Global Heads, Chief Scientific Officers, Directors, Principal Scientists, Franchise Heads and Investigators in:
• High-Throughput/High-Content Screening Operations• Bioanalytical Development • Compound Profiling • Drug Discovery/Validation• Cellular Imaging• Lead Generation• In Vitro Sciences• ADMET• Pre-clinical Development• Medicinal Chemistry• Toxicology• Stem Cell Technologies & Platforms• Pharmacovigilance and Safety Testing• Chemistry and Bioapplications• GPCR/Kinases/Molecular Pharmacology• External/Contract Research• Pharmacokinetics/Pharmacodynamics• Cellular Research and Development• Business Development• Investment and Venture Capital
Associate Sponsor:
InvivoSciencesLLCisafrontierindevelopingnextgeneration3Dcellcultureandassaysystems,providingunprecedentedsolutionsforbiomedicalresearch,cosmetics,discovery,andtoxicologyscreening.Two-dimensionalcellculturesusedduringearlyphaseresearchdonotreflectthereal,internal,3Denvironment,andfalselyindicatepotentialresultsfromanimalstudies.Applicationofourproducts,ahigh-throughput
screeningdevice(PalpatorTM)andplasticconsumablesfor3Dcellculturesystems,cannarrowthisgap.Thesystemprecisely,rapidly,andcost-effectivelyquantifiestheeffectsofdrugcandidates,chemicals,andgeneproductsonthephysiologicalpropertiesofreconstitutedtissues(3Dcellcultures),betterreflectinginvivotissue/organfunctions.For further information please visit: www.invivosciences.com
Lonzaisoneoftheworld’sleadingsupplierstothepharmaceutical,healthcareandlifescienceindustries.Lonza’sBioscienceDivisionprovidesinnovative,reliableproductsandservicesfordrugdiscoverycell
biologyandmolecularbiologyresearchandpreclinicalscreening.Wefocusonprimarycellsupply,includingdiseasedcells,stemcellderivedcells,immortalizedcells,biosensorcells,transfectionofdifficultcellsandcellexpansionservices.Wealsoofferimprovedpredictionfromcellmodels,includingcontextualcell-basedassaysfortoxicityandmechanism-of-actionassessment.WemakereagentproductioneasierforourcustomerswithourCellsonDemand™Servicesandputtingtheassaysyoualreadyuseintobiologicallyrelevantprimarycells.For further information please visit: www.lonza.com
ScottishBiomedicaloffersafullrangeofbiologyservicesfromproteinexpressionandexpressionoptimisationthroughtoinvitroscreening,cellbasedassaysandinvivomodels.Ourteam
willdesignandvalidateuniqueassaystosuityourspecificneeds,usingprimarycellsorcustommadecelllinesofyourchoice.Asexpertsincellsignaling,wespecialiseincell-basedandinvitroassaystodeterminecompoundeffectsontargetssuchasPDEs,HDACs,ionchannels,GPCRs,andkinases.For further information please visit: www.scottish-biomedical.com
HamamatsuPhotonicsisaworld-leadingmanufacturerofoptoelectroniccomponentsandsystemsandprovidessolutionsforawidevarietyofapplicationsincludingimagingdevicesforLife
Sciences.Wewillintroduceourcamera-baseddispensingandimagingrange,theFDSSseriesforfluorescenceandluminescence.TheFDSS7000isafullymodularHTSsystemandtheFDSSµCELLisspecificallydesignedforsmallthroughputandassaydevelopment.BasedonourfamouscamerarangetheFDSSseriesprovideshighsensitivityandfastreadouttimesofafewminutes.For further information please visit: www.hamamatsu.co.uk
MerckMilliporeistheLifeSciencedivisionofMerckKGaAofGermanyandoffersabroadrangeofinnovative,performanceproducts,servicesandbusinessrelationshipsthatenableourcustomers’successinresearch,developmentandproductionofbiotechandpharmaceuticaldrugtherapies.Throughdedicatedcollaborationonnewscientificand
engineeringinsights,andasoneofthetopthreeR&DinvestorsintheLifeScienceToolsindustry,MerckMilliporeservesasastrategicpartnertocustomersandhelpsadvancethepromiseoflifescience.HeadquarteredinBillerica,Massachusetts,thedivisionhasaround10,000employees,operationsin64countriesandproforma2009revenuesof$2.9billion.MerckMilliporeoperatesasEMDMilliporeintheU.S.andCanada.For further information please visit: www.merckmillipore.com
Media Partners:PharmiWeb.comistheleadingindustry-sponsoredportalforthepharmaceuticalsector.Supportedbymostoftheleading
pharmaceuticalcorporations,PharmiWeb.comprovidesdynamicreal-timenews,features,eventslistingsandinternationaljobstoindustryprofessionalsacrossEuropeandtheUS.For further information please email: [email protected]
BIOTECHNOLOGYEUROPEisownedbyBIOTECHNOLOGYWORLD.ItisbasedandlocatedinWarsaw,Poland.BiotechnologyWorldwasfoundedin2007toprovidetheworld’sbiotechandpharma
informationandmarkettomakeituniversallyaccessibleandusefulforscientificandbusinessprocesses.ItsfirststeptofulfillingthatmissionwasbuildingtheBIOTECHNOLOGYEUROPEplatformthatwillallowaquickspreadofinformationindifferentchannels.BIOTECHNOLOGYEUROPEofferscompaniescompletedinternetpublicrelations,publicationandmarketingsolutions.OneofthemainsgoalsofBIOTECHNOLOGYEUROPEistointegratetheBiotechandPharmaSectorinEuropetoglobalbiotechnology,pharmaceuticalandlifescienceactivities.For further information please visit: www.biotechnology-europe.com
FuturePharmaceuticalshasforgedpowerfulrelationshipswithkeyindustryleaderstoprovideaplatformforsuccessfulbrandrecognition,andforseniordecision-makerstohavethemeans
toprocureandplanimplementationstrategiesbasedonthetopicscovered.Positionedtobeanauthoritativeresourcewithintoppharmacompaniesaswellassmall,specialty,andbiotech,FuturePharmaceuticalsmagazineisgearedtocreateadeeppenetrationintoahighlytargetedandresponsiveaudience,bridgingthegapbetweentheindustries’topissuesandthesolutionstop-tiervendorscanprovide.For further information please visit: www.futurepharmaus.com
InPharmistheonlineplatformforexclusivepharmaceuticalnews,comment,contracts,services,jobsandeventsandishometoInPharmjobs.com,PharmafileandPharmafocus.
For further information please visit: www.In-Pharm.com
Driving the Industry Forward | www.futurepharmaus.com
Sponsorship and exhibition opportunitiesThiseventoffersauniqueopportunitytomeetanddobusinesswithsomeofthekeyplayersinthepharmaceuticalandbiotechindustries.Ifyouhaveaserviceorproducttopromote,youcandosoatthiseventby:
•Hostinganetworkingdrinksreception•Takinganexhibitionspaceattheconference•Advertisinginthedelegatedocumentationpack•Providingbrandedbags,pens,gifts,etc.
Ifyouwouldlikemoreinformationontherangeofsponsorshiporexhibitionpossibilitiesforvisiongain's2ndAnnualCell-BasedAssaysConference,pleasecontactus:
Damian Gorman, +44 (0)20 7549 9934 [email protected]
P H O T O N I S O U R B U S I N E S S
Pre-Conference Interactive Workshop2nd Annual Cell-Based Assays
Tuesday 11th October 2011
Industrial application of pluripotent stem cells and their derivativesHigh-content screening as a valuable tool for drug discovery and toxicity testing
Mikael Englund, SeniorScientist,SiteManager, Cellartis
Daniella Steel, SeniorScientist,ProjectLeader, Cellartis
Paul Andrews, SeniorScientist,DrugDiscoveryUnit, University of Dundee
Petter Björquist, SeniorPrincipalScientist,ProjectManager, Cellartis
Anders Aspegren, SeniorScientist,ProductionManager, Cellartis
Led by:
About your workshop leaders:
Mikael Englund
Mikael Englund has been part of Cellartis’ stem cell team since 2001 and moved to develop UK operations in Dundee 2007. The UK site manufactures large scale volumes of human ESCs and develops advanced culture technology and engineering tools, e.g. for drug screening and other applications. The facility also partners with Novo Nordisk to find a cure for diabetes.
Mikael’s responsibilities at Cellartis have ranged from fundamental hESC research to industrial production of hESCs for screening. He has a large network in the field and more than nine years experience of the challenges of commercial stem cell business. He has a M.Sc. in molecular biology and a Ph.D. in Medicine.
Daniella Steel
Daniella Steel is a senior scientist at Cellartis, within R&D at the Gothenburg site, Sweden. Daniella is involved in the differentiation and application of stem cell-derived cardiomyocytes. Her interests include the innovation and commercialision of stem cell based tools for drug discovery and safety assessment. Through developing industrial applications, Daniella has worked closely with pharmaceutical industry and biosensor technology providers.
Daniella earned her Ph.D. in electrophysiology from the faculty of Medicine, Imperial College, London. Her background in establishing cellular disease models continued with international experience at McGill University, Canada, and at Chalmers University of Technology, Sweden.
Paul Andrews
I obtained a Biochemistry B.Sc and Ph.D in Molecular Biology from the University of Sheffield. In 1993 I moved to the University of Dundee, to pursue my interest in signalling, first using budding yeast and, later, using human cells. Since 2007 I have been leading the Stem Cell Programme in the Drug Discovery Unit at Dundee. I established the high-content screening capabilities and headed several successful screening campaigns using human ES cells or their derivatives. My current interests lie in targeting signalling pathways using small molecules to: engineer cell fate; induce nuclear reprogramming and target cancer stem cells.
Timings: 09:30 Registration and coffee An introduction to pluripotent stem cells, Industrialisation of stem cells Introduction to high-content screening and assay design Screen execution and follow-up12:40 Lunch13:40 Case studies, lessons learnt, Stems cells in predictive toxicology Stem cell derivatives in screening15:00 Panel discussion Q1: How predictive are stem cell based discovery systems? Is there
added value above existing systems? Q2: Are stem cell based platforms compatible with the time lines and
automation systems required in an industrial environment? Q3: What is the future for stem cell based discovery systems in the drug
discovery pipeline
About the workshopDemands for better models of human disease and more predictive screening assays to reduce late stage drug attrition, have promoted a growing interest in applying pluripotent stem cells (PSCs) and their derivatives at various points in the drug discovery pipeline. Furthermore, the use of PSCs in identifying small molecules active in directing cellular reprogramming or differentiation, is a particularly promising tool for the regenerative medicine field. This workshop will review recent advances in the field including issues surrounding cell quality, supply and banking, assay development and the screening process. It will evaluate the benefits of using 3D models, as well as address the efficacy of PSC-based models for assessing human developmental, cardiac and hepatic toxicity. Case studies of different compound screening campaigns using PSCs and their derivatives, will permit exploration of the field in detail.
Lessons learned:• Examples of scaled up pluripotent stem cell culture for industrial applications
• Assay design considerations
• Examination of screening platforms and strategies
• A review of stem cell derivatives for screening
About Cellartis:Cellartis AB is a Swedish/British biotechnology company focused on pluripotent stem cells and technology for drug discovery research, toxicity testing and regenerative medicine. Since 2001, Cellartis has worked globally with industry and academia, platform providers and end users, to develop the next generation of advanced stem cell products and technologies. The company leverages deep experience in stem cell handling, scale up and differentiation into mature and functional human cells. The company was first in the world to bring to the market human embryonic stem (hES) cell-derived hepatocytes and cardiomyocytes for use as drug discovery tools today.
About The Drug Discovery Unit, University of DundeeThe Drug Discovery Unit (DDU) based in the College of Life Sciences at the University of Dundee, is a unique example of academic drug discovery. The remit of the DDU is to tackle high-risk and/or novel targets in areas of unmet medical need. The DDU has all of the capabilities required for early phase drug discovery: from assay development, HTS and cell biology, to medicinal chemistry, structural biology, computational chemistry and ADME/DMPK. All of these capabilities operate under one management structure to ensure an integrated approach and rapid progress.Currently the team is about 30 people and includes substantial experience from the pharmaceutical/ biotech sector. Since 2007 the DDU has collaborated with Cellartis using hES cells and their derivatives in high-throughput screening campaigns, to find small molecules able to manipulate stem cell fate.
Panellists:
09:00 Registration and refreshments
09:30 Opening address from the Chair Rachel Russell
Director,PrimaryPharmacologyGroupPfizer
09:40 Impact of new technologies for cellular screening along the drug value chain
•Primary,stemcell,3Dandlabel-freescreensemployingcellularassays •Ionchannelscreening •Atomicforcemicroscopyindrugdiscoveryanddevelopment
Mark Slack, GroupLeader,CellularAssays,Evotec
Clemens Möller, ProfessorofBiophysics,Albstadt-Sigmaringen University
10:20 A novel, rapid and automated method for creating 3D tissue models to study complex cell behaviour
•Whattypeofinformationcan3Dtissuemodelsprovide? •Whatispreventingwidespreadadoptionof3Dtissuemodels? •Theroutetoscalableandtuneable3Dtissuemodels
Rosemary Drake ChiefScientificOfficerTAP Biosystems
11:00 Morning refreshments
11:20 Unlocking the potential of 3D cell culture with Alvetex technology
•2Dvs3Dcellculture •Developmentofuniquescaffold •Optimizingroutine3Dcellculture
Stefan Przyborski FounderandChiefScientificOfficerReinnervate
11:40 Application of a 3D tumour cell culture model to compound screening
•Threedimensionalgrowthassayandimageanalysis •Plate-based,label-free,high-contentanalysisevaluation •Screeningvalidationandpre-clinicalresults
Miroslav Cik ResearchFellowJanssen Pharmaceutica (Johnson & Johnson)
12:20 Integration of label-free detection methods in GPCR drug discovery
•Comparisonofimpedanceandopticalread-outs •RecombinantcellsvsendogenousGPCRsignalling •Nativereceptoractivityindisease-relevantcells
Magdalena Birker-Robaczewska SeniorLabHead,Cardiovascular&FibrosisBiologyActelion Pharmaceuticals
13:00 Networking lunch
14:00 Rapid non-invasive analysis of live cells •GlobalfingerprintingofcellswithlivecellRamanspectroscopy •Applicationsintoxicology •Applicationsincelldifferentiation
Molly Stevens ProfessorofBiomedicalMaterialsandRegenerativeMedicineImperial College London
14:40 Label-free methods- where are we and what are the prospects for the future?
Despitetheirincreasingimportance,whenwillitbecommerciallyviabletointegratenon-invasivemethodsintoHTscreening?Canrelevantquantitiesofprimarycellsbesecuredtoenablethis?Theutilityoflabel-freemethodstoreduceattritionratesandtheconditionsnecessarytoobtainreal-time,quantitativemeasurementswillbethoroughlyassessed.Jointhislivelysessionandemailyourquestionsto:[email protected].
Chair: Magalie Rocheville,Investigator,GlaxoSmithKline
Mark Slack, GroupLeader, Cellular Assays, Evotec
Miroslav Cik, ResearchFellow,Janssen Pharmaceutica (Johnson & Johnson)
Molly Stevens, ProfessorofBiomedicalMaterialsandRegenerativeMedicine,Imperial College London
15:20 Development of cell-based methodologies relevant to ion channel drug discovery
•Directandindirectmeasurementofligand-andion-gatedchannelsinrecombinantlines
•Electrophysiologyusingstemcellderivedneurons •Nativetissueelectrophysiology
Fiona Harris SeniorScientistScottish Biomedical
15:40 Afternoon refreshments
16:00 Development of a multiplexed gene expression assay in primary neurons
•Quantificationofcompound-inducedchangestoexpressionofpain-relatedgenes •Challengesofusingnativeneuronalcellsasreagentsforprimaryscreening •Applicationoftheassayforcompoundprofilingandnewtargetidentification
Darren Cawkill AssociateDirector,PrimaryPharmacologyGroupPfizer
16:40 The FDSS series: a versatile platform for HTS and assay development
•Primarycultureandcelllineassaysinfluorescenceandluminescence •Wholedispensingandimagingscreeningsystemsforcell-basedassays •Applications:newepilepsymodelandluminescencemultiplexing
Christelle Catone FDSSApplicationScientist,SystemsDivisionHamamatsu Photonics
17:00 Executable cell biology •Mathematicalversuscomputationalmodels •Modelsforexecutablebiology •Challengesfortestingdynamicsincomplexsystems
Jasmin Fisher Researcher,ExecutableBiologyMicrosoft Research Cambridge
17:40 Closing remarks from the Chair
17:50 Networking drinks Take your discussions further and build new
relationships in a relaxed and informal setting
Day 12nd Annual Cell-Based Assays
Wednesday 12th October 2011
Due to unforeseen circumstances the programme may change and visiongain reserves the right to alter the venue and/or speakers c Copyright visiongain Ltd, 2011
PAN
EL D
ISC
USS
ION
Day 22nd Annual Cell-Based AssaysThursday 13th October 2011
09:00 Registration and refreshments
09:30 Opening address from the Chairs Joanne Bowes
PrincipalScientist/TeamLeader,SafetyandSecondaryPharmacologyAstraZeneca
09:40 Early toxicity testing: prediction and tissue-specific models
•Earlytoxicitytestingparadigms •Cellularmodelsfortoxicitytesting,focusingontheliver,lungandheart •Predictionmodelsusingglobalexpressionprofiling
Stefan Otto Mueller Director,Early,GeneticandMolecularToxicologyMerck Serono
10:20 Protein-fragment complementation assays and compound profiling
Anthony Pitt TechnicalDirectorAssaysandTechnologyDevelopmentLonza
10:40 Key considerations in the development of stem cell assays in predictive toxicology
•Theneedforimproveddrugscreeningmodelstopredictriskforman •Prerequisitesforsuccessfuldevelopmentofstemcellsassaysintoxicitytesting •SC4SMPredictiveToxicologyConsortium:challengesand
futureopportunities
Frank W. Bonner ChiefExecutiveStem Cells for Safer Medicines
11:20 Morning refreshments
11:40 Therapeutic and research potential of human stem cells (hSCs) – the GE Healthcare perspective
•HowhSCswillrevolutionisemedicalcarethroughregenerativestrategies •HowhSCswillimprovequality,priceandaccessibilityofnewpharmaceuticals •MaximisinghSCuseinbigpharmadrugdiscoveryandsafetyassessmentstudies
Stephen Minger GlobalHeadofR&D,CellularTechnologiesGE Healthcare
12:20 Human pluripotent stem cells (hPSCs) and their use in drug discovery and cellular assays
•Importanceofscaleablesystemsforindustrialstemcellproduction •CellulartoxicitytestingusinghPSCderivedcardiomyocytesandhepatocytes •hPSCtechnologiescomparedtotraditionalinvitroandinvivoassays
Petter Björquist SeniorPrincipalScientist,ProjectManagerCellartis
13:00 Networking lunch
14:00 Enabling technology to enhance cell differentiation and function in vitro
•Celldifferentiationin3DcultureusingprimaryMSCsandpluripotentstemcells •Developmentofsmallmoleculestocontrolreproduciblehumanneural
differentiationinvitro •Useofsmallmoleculestodifferentiatea3Dskinequivalentmodelwith
humankeratinocytes
Stefan Przyborski FounderandChiefScientificOfficerReinnervate
14:20 Predicting idiopathic cardiotoxicity with 3D heart tissues: combining rodent and human models
•Cardiaccontractilityresponsetoapanelofcardio-toxicdrugswithiPSCandESCbased3Dengineeredhearttissues
•Cost-effectiveandthemostpredictivescreeningapproach •Identifyingidiopathiccardiotoxicitymechanismsforsearchingpreventive
strategies
Tetsuro Wakatsuki Co-FounderandChiefScientificOfficerInvivoSciences
14:50 Generating metabolically active hepatocytes from pluripotent stem cells
•Stemcellsofferanunlimitedsourceofhepaotcytesforhumandrugscreening •Stemcellderivedhepatocytesexhibitphenotypicinstabilityinculture •Wehaveidentifiedanovelsupportwhichstabiliseshepatocellularphenotype
David C. Hay PrincipalInvestigator,MRCCentreforRegenerativeMedicineUniversity of Edinburgh
15:30 Afternoon refreshments
15:50 Opportunities and challenges for human stem cells in drug screening
WillhESandhPS/iPS-derivedspecialisedcellsbetterreflecthumanvariationtotoxicagentsandmatchbiologicalpossibilitieswithend-userconstraints?Canidiopathicandethniclibrariesaidpatientstratification,orwillcellularmodelsremainoversimplifications?Whatnewinsightswillorganogenesisanddiseasemodelsprovide?Answerstotheseandothermatters,includingregulatoryrequirementsandup-scalingforrobustindustrialproductionwillbeaddressed.Pleaseemailyourquestionsforthepanelto:[email protected].
Chair: Julie Holder, PreclinicalDirector,StemCellDPU,GlaxoSmithKline
Stephen Minger, GlobalHeadofR&D,CellularTechnologies,GE Healthcare
Petter Björquist, SeniorPrincipalScientist,ProjectManager,Cellartis
Frank W. Bonner, ChiefExecutive,Stem Cells for Safer Medicines
David C. Hay, PrincipalInvestigator,MRCCentreforRegenerativeMedicine,University of Edinburgh
16:30 Chair’s closing remarks
16:40 End of conference
PAN
EL D
ISC
USS
ION
How to bookEmail:[email protected] Web:http://www.visiongain.com/cell-based-assays
UK Office:Tel: +44 (0) 20 7549 9961 Fax:+44(0)2075499932 VisiongainLtd230CityRoadLondonEC1V2QYUK
General informationVenue:Venue:Directions:VisiongainConferenceCentre230CityRoad,London,EC1V2TT.UnitedKingdom.ClosesttubestationisOldStreet(NorthernLine).Accommodation:ThistleCityBarbican,CentralStreet,Clerkenwell,London,EC1V8DS,Phone:08713769004/+448453058304,Fax:08713769104/+448453058343http://www.thistle.com/en/hotels/united_kingdom/london/thistle_city_barbican/index.htmlTravelodgeLondonCityRoadHotel,7-12CityRoad,London,EC1Y1AE,Tel:08719846333,Fax:02076282503,http://www.travelodge.co.uk/search_and_book/hotel_overview.php?hotel_id=340
Payment terms:Visiongainrequirethefullamounttobepaidbeforetheconference.VisiongainLtdmayrefuseentrytodelegateswhohavenotpaidtheirinvoiceinfull.Acreditcardguaranteemayberequestedifpaymenthasnotbeenreceivedinfullbeforetheevent.VisiongainLtdreservestherighttochargeinterestonunpaidinvoices.
Substitutions/name changes or cancellations: Thereisa50%liabilityonallbookingsoncemade,whetherbypost,fax,emailorweb.Thereisanorefundpolicyforcancellationsreceivedonorafteronemonthbeforethestartoftheevent.Shouldyoudecidetocancelafterthisdate,thefullinvoicemustbepaid.Conferencenoteswillthenbesenttoyou.Unfortunately,weareunabletotransferplacesbetweenconferences.However,ifyoucannotattendtheconference,youmaymakeasubstitution/namechangeatanytime,aslongasweareinformedinwritingbyemail,faxorpost.Namechangesandsubstitutions must be from the same company or organisation and are not transferable betweencountries.Pleasenotethatdiscounteddelegatesplacesatavisiongaineventarenonrefundable.
Invoice alterations:Therewillbeanadministrationchargeof£50foranychangestoaninvoice,excluding substitutions/name changes, requested by the customer. This will be charged to thecustomerbycreditcardpriortothechangesbeingmade.
Indemnity: Visiongain Ltd reserves the right to make alterations to the conference/executivebriefingcontent,timing,speakersorvenuewithoutnotice.TheeventmaybepostponedorcancelledduetounforeseeneventsbeyondthecontrolofvisiongainLtd.Ifsuchasituationarises,wewilltrytorescheduletheevent.However,visiongainLtdcannotbeheldresponsibleforanycost,damageorexpenses,whichmaybeincurredbythecustomerasaconsequenceoftheeventbeingpostponedorcancelled.Wethereforestronglyadviseallourconferenceclientstotakeoutinsurancetocoverthecostoftheregistration,travelandexpenses.
Data Protection: Visiongain Ltd gathers and manages data in accordance with the DataProtectionAct1988.YourpersonalinformationcontainedinthisformmaybeusedtoupdateyouonvisiongainLtdproductsandservicesviapost,telephone,faxoremail,unlessyoustateotherwise.Wemayalsoshareyourdatawithexternalcompaniesofferingcomplementaryproductsorservices.Ifyouwishforyourdetailstobeamended,suppressedornotpassedontoanyexternalthirdparty,pleasesendyourrequesttotheDatabaseManager,visiongainLtd,BSGHouse,226-236CityRoad,London,EC1V2QY.Alternatively,youcanvisitourwebsiteatwww.visiongain.comandamendyourdetails.Pleaseallowapproximately30daysforyourremovalorupdaterequesttobeappliedtoourdatabase.Followingyourremovalorupdaterequest,youmayreceiveadditionalpiecesofcommunicationfromvisiongainLtdduringthetransitionalperiod,whilstthechangesarecomingintoeffect.
Fee: Theconferencefeeincludeslunch,refreshmentsandconferencepapersprovidedontheday.This feedoesnot include travel, hotel accommodation, transfersor insurance, (whichwe stronglyrecommendyouobtain).
VAT: VATwillbechargedatthelocalrateoneachconference.DelegatesmaybeabletorecoverVATincurredbycontactingEurocashCorporationplc+44(0)1273325000,eurocash@eurocashvat.com.Eurocashspecialiseinrecoveringcross-borderVAT.
How we will contact you: VisiongainLtd’spreferredmethodofcommunicationisbyemailandphone.Pleaseensurethatyoucompletetheregistrationforminfullsothatwecancontactyou.
Unable to attendObviouslynothingcomparestobeingtherebutyouneednotmissout.Simplyticktheboxandsendwithyourpayment.YouwillreceivespeakertalksinPDFstwoweeksaftertheevent.
Yes, please send me speaker talks Price£550 VAT:£110 Total:£660
Conf.codePP
Standard PricesConference and workshop Fee: £1699 VAT: £339.80 Total: £2038.80
Conference only Fee: £1299 VAT: £259.80 Total: £1558.80
Workshop only Fee: £599 VAT: £119.80 Total: £718.80
Number of bookings: Total cost:
Promotional Literature DistributionDistribution of your company’s promotional literature to all conference attendees
Fee: £999 VAT: £199.80 Total: £1198.80
Details
Forename: Surname:
JobTitle: Company:
MainSwitchboardNumber:
Address:
Country: Postcode:
Phone: Fax:
Email:
Signature:
IconfirmthatIhavereadandagreetothetermsandconditionsofbooking
Methods of payment
Paymentmustbemadeinsterling
By Mail: Completeandreturnyoursignedregistrationformtogetherwithyourchequepayable
toVisiongainLtdandsendto:visiongainLtd,BSGHouse,226-236CityRoad,London,EC1V2QY,UK
By Fax: Completeandfaxyoursignedregistrationformwithyourcreditcarddetails
to+44(0)2075499932
By Phone:Calluson+44(0)2073366100withyourcreditcarddetails
By Credit Card:Fillinyourcarddetailsbelowandfaxbackto+44(0)2075499932
By Bank Transfer:
VisiongainLtd A/C:visiongainLtd
BarclaysBank SortCode:20-71-64
PiccadillyBranch AccountNo:60387118
48RegentStreet SwiftCode:BARCGB22
London,W1B5RA IBAN:GB80BARC20716460387118
Please debit my credit card:
Access MasterCard Visa AmericanExpress
Cardnumber:
ExpiryDate:
Securitynumber(last3digitsonbackofcreditcard):
Signature:
Cardholder’sname:
News updates
Pleasetickifyoudonotwanttoreceiveemailnewsupdatesinthefuture
Registration Form2nd Annual Cell-Based Assays
11th - 13th October 2011, London, UK
www.visiongain.com/cell-based-assays
2nd Annual Cell-Based Assays 11th - 13th October 2011Location:VisiongainConferenceCentre
Address:230CityRoadLondonEC1V2TTUK
City Road
Old Street
City Road
Pentonville Road
Old Street
Angel